stockrowSmith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Total debt
Smith & Nephew SNATS, Inc.'s total debt at the end of fiscal 2025 was $3.2B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $3.2B. Over the past ten years it has ranged from $1.3B (fiscal 2018) to $3.4B (fiscal 2020); the current reading is higher than 82% of that period. Smith & Nephew SNATS, Inc. ranks 8th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $3.2B | (2.49%) |
| FY2024 | $3.3B | 40.49% |
| FY2023 | $2.3B | (14.49%) |
| FY2022 | $2.7B | (4.78%) |
| FY2021 | $2.8B | (15.06%) |
| FY2020 | $3.4B | 69.77% |
| FY2019 | $2.0B | 51.81% |
| FY2018 | $1.3B | (8.57%) |
| FY2017 | $1.4B | (9.02%) |
| FY2016 | $1.6B | 9.07% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $3.2B | 1.10% |
| Dec 2025 | $3.2B | (3.64%) |
| Jun 2025 | $3.3B | 1.20% |
| Dec 2024 | $3.3B | (0.52%) |
| 18 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SNN Smith & Nephew SNATS, Inc. | $3.2B |
| BRKR Bruker Corporation compare | $1.7B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $1.2B |
| BIO Bio-Rad Laboratories, Inc. compare | $1.2B |
| PODD Insulet Corporation compare | $962.1M |
| GMED Globus Medical, Inc. compare | $443.4M |
| TXG 10x Genomics compare | $98.0M |
| GKOS Glaukos Corporation compare | $66.9M |
| PEN Penumbra, Inc. compare | $19.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement